These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 11165117

  • 1. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
    Luzzaro F, Perilli M, Amicosante G, Lombardi G, Belloni R, Zollo A, Bianchi C, Toniolo A.
    Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
    Wang JT, Chen PC, Chang SC, Shiau YR, Wang HY, Lai JF, Huang IW, Tan MC, Lauderdale TL, TSAR Hospitals.
    BMC Infect Dis; 2014 Sep 05; 14():486. PubMed ID: 25192738
    [Abstract] [Full Text] [Related]

  • 3. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.
    Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G, Italian ESBL Study Group.
    Antimicrob Agents Chemother; 2002 Jan 05; 46(1):196-202. PubMed ID: 11751134
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of a modified double-disc synergy test for detection of extended spectrum beta-lactamases in AMPC beta-lactamase-producing proteus mirabilis.
    Khan MK, Thukral SS, Gaind R.
    Indian J Med Microbiol; 2008 Jan 05; 26(1):58-61. PubMed ID: 18227600
    [Abstract] [Full Text] [Related]

  • 5. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY, Chen YH, Tang HJ, Huang CC, Liao CH, Chu FY, Chuang YC, Sheng WH, Ko WC, Hsueh PR.
    Diagn Microbiol Infect Dis; 2014 Nov 05; 80(3):222-6. PubMed ID: 25139843
    [Abstract] [Full Text] [Related]

  • 6. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital.
    Kim JY, Park YJ, Kim SI, Kang MW, Lee SO, Lee KY.
    J Antimicrob Chemother; 2004 Dec 05; 54(6):1144-7. PubMed ID: 15546971
    [Abstract] [Full Text] [Related]

  • 7. [Enzymatic resistance to beta lactam antibiotics within the genus Proteus and evaluation of Proteus mirabilis phenotypes and genotypes for resistance to third- and fourth-generation cephalosporins].
    Rodríguez C, Radice M, Perazzi B, Castro S, Juárez J, Santini P, Vay C, Famiglietti A, Gutkind G.
    Enferm Infecc Microbiol Clin; 2005 Mar 05; 23(3):122-6. PubMed ID: 15757582
    [Abstract] [Full Text] [Related]

  • 8. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
    Livermore DM, Yuan M.
    J Antimicrob Chemother; 1996 Sep 05; 38(3):409-24. PubMed ID: 8889716
    [Abstract] [Full Text] [Related]

  • 9. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S, Gaind R, Ranjan R, Deb M.
    J Infect Dev Ctries; 2009 Nov 21; 4(1):24-9. PubMed ID: 20130375
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
    Liu HC, Hung YP, Lin HJ, Liu HC, Lee JC, Wu YH, Li CW, Li MC, Ko WC.
    J Microbiol Immunol Infect; 2016 Aug 21; 49(4):584-90. PubMed ID: 26692184
    [Abstract] [Full Text] [Related]

  • 11. Molecular Characterization of β-Lactam Resistance and Antimicrobial Susceptibility to Possible Therapeutic Options of AmpC-Producing Multidrug-Resistant Proteus mirabilis in a University Hospital of Split, Croatia.
    Rubic Z, Soprek S, Jelic M, Novak A, Goic-Barisic I, Radic M, Tambic-Andrasevic A, Tonkic M.
    Microb Drug Resist; 2021 Feb 21; 27(2):162-169. PubMed ID: 32429775
    [Abstract] [Full Text] [Related]

  • 12. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S, Marre R.
    Infection; 1991 Feb 21; 19(2):106-9. PubMed ID: 1646771
    [Abstract] [Full Text] [Related]

  • 13. IMP-27, a Unique Metallo-β-Lactamase Identified in Geographically Distinct Isolates of Proteus mirabilis.
    Dixon N, Fowler RC, Yoshizumi A, Horiyama T, Ishii Y, Harrison L, Geyer CN, Moland ES, Thomson K, Hanson ND.
    Antimicrob Agents Chemother; 2016 Oct 21; 60(10):6418-21. PubMed ID: 27503648
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q, Zhang H, Cheng J, Xu Z, Xu Y, Cao B, Kong H, Ni Y, Yu Y, Sun Z, Hu B, Huang W, Wang Y, Wu A, Feng X, Liao K, Shen D, Hu Z, Chu Y, Lu J, Su J, Gui B, Duan Q, Zhang S, Shao H.
    Int J Antimicrob Agents; 2015 May 21; 45(5):485-90. PubMed ID: 25600890
    [Abstract] [Full Text] [Related]

  • 15. [Characteristic of resistance to beta-lactam antibiotics of nosocomial strains of Proteus mirabilis].
    Ivanov DV.
    Zh Mikrobiol Epidemiol Immunobiol; 2008 May 21; (6):75-8. PubMed ID: 19189465
    [Abstract] [Full Text] [Related]

  • 16. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D, Yinnon AM, Broide E, Rudensky B.
    Chemotherapy; 2007 May 21; 53(3):185-9. PubMed ID: 17347564
    [Abstract] [Full Text] [Related]

  • 17. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
    Kanayama A, Iyoda T, Matsuzaki K, Saika T, Ikeda F, Ishii Y, Yamaguchi K, Kobayashi I.
    Int J Antimicrob Agents; 2010 Oct 21; 36(4):340-2. PubMed ID: 20609568
    [Abstract] [Full Text] [Related]

  • 18. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
    Giakkoupi P, Tzelepi E, Legakis NJ, Tzouvelekis LS.
    J Antimicrob Chemother; 1999 Jan 21; 43(1):23-9. PubMed ID: 10381097
    [Abstract] [Full Text] [Related]

  • 19. An evaluation of the in vitro activity of piperacillin/tazobactam.
    Daley D, Mulgrave L, Munro R, Neville S, Smith H, Dimech W.
    Pathology; 1996 May 21; 28(2):167-72. PubMed ID: 8743825
    [Abstract] [Full Text] [Related]

  • 20. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
    Aragón LM, Mirelis B, Miró E, Mata C, Gómez L, Rivera A, Coll P, Navarro F.
    J Antimicrob Chemother; 2008 May 21; 61(5):1029-32. PubMed ID: 18292096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.